Presentation to feature Company’s novel therapeutic candidates under development in collaboration with leading academic institutions ENGLEWOOD CLIFFS, NJ, Oct. 06, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that CEO Eric Weisblum will…


Previous articleNuminus Develops Mushroom Tea for Use in Psychedelic Research
Next articleAlberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health